Skip to main content
. 2020 May 7;15(5):e0232754. doi: 10.1371/journal.pone.0232754

Fig 4. Survival of patients with actionable mutant fragments detected in plasma.

Fig 4

(A) Overall survival according to whether KRAS mutant fragments were or were not detected in baseline plasma cfDNA (n = 51, p<0.05). (B) Kaplan-Meier curves for overall survival in patients according to cfDNA concentration. Survival was worse in patients with higher cfDNA concentrations (>10 ng/mL, n = 17) than in those with lower cfDNA concentrations (≤10 ng/mL, n = 34) (log-rank test, p<0.05). (C) Kaplan-Meier curves for overall survival according to whether cfDNA TP53 mutants were detected. Overall survival was worse in patients with TP53 mutants, although this did not reach statistical significance (Log-rank test, p<0.1). cfDNA, cell-free DNA; MT, mutant detected; ND, mutant not detected.